论文部分内容阅读
目的观察阿奇霉素治疗小儿支原体肺炎的临床疗效和安全性。方法将50例小儿支原体肺炎随机分为2组,治疗组使用阿奇霉素;对照组使用红霉素。结果治疗组总有效率92%。对照组总有效率72%。两组比较差异有统计学意义(P<0.05)。治疗组和对照组其胃肠道不良反应发生率分别为4例(14%)和12例(48%),两组比较差异有统计学意义(P<0.05)。结论阿奇霉素治疗小儿支原体肺炎的临床疗效优于红霉素,且耐受性好,不良反应低,值得临床推广应用。
Objective To observe the clinical efficacy and safety of azithromycin in treating children with mycoplasma pneumonia. Methods 50 cases of children with mycoplasma pneumonia were randomly divided into two groups, the treatment group used azithromycin; the control group used erythromycin. Results The total effective rate of 92%. The control group a total effective rate of 72%. The difference between the two groups was statistically significant (P <0.05). The incidences of gastrointestinal adverse reactions in treatment group and control group were 4 cases (14%) and 12 cases (48%), respectively. There was significant difference between the two groups (P <0.05). Conclusion Azithromycin is superior to erythromycin in the treatment of children with mycoplasma pneumonia and has good tolerability and low adverse reactions, which is worthy of clinical application.